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Background: The availability of Sugammadex has increased options 
for Certified Registered Nurse Anesthetists’ (CRNAs) and their 
choice of neuromuscular reversal agents, however administration is 
impacted by a variety of provider and institutional factors.  
Objectives: The purpose of this study was to examine and describe 
the personal and institutional factors impacting the use of 
Sugammadex in Illinois by CRNAs.  
Method: A qualitative study design using an open-ended survey 
yielded 209 responses.  The three main themes that emerged were 1) 
Why CRNAs choose to use or avoid Sugammadex 2) How CRNAs 
dose Sugammadex and 3) Practice variations existing within the 
clinical setting. 
Results: The most commonly reported subthemes included depth of 
blockade/dosing of paralytic, underlying disease pathology, size of 
the patient, and cost considerations or availability at their institution. 
Conclusion: Based upon these main themes and subthemes, it is 
recommended that institution wide policies be created to reduce 
variability in provider administration practices if Sugammadex is not 
widely accepted as standard reversal.  
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